REVEAL Lite 2 risk calculator a simplified model to assess mortality risk in PAH


February 23, 2021

3 min read


Disclosures: The study was funded by Janssen Pharmaceuticals, the sponsor of the REVEAL Registry. Benza reports he received grants from the American Heart Association, Bayer, the National Heart, Lung, and Blood Institute, and United Therapeutics; and received research support and served as a paid consultant for Janssen Please see the study for all other authors’ relevant financial disclosures.


Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .



We were unable to process your request. Please try again later. If you continue to have this issue please contact

Back to Healio

Use of an abridged version of the REVEAL 2.0 risk calculator, REVEAL Lite 2, provided a simplified method of mortality risk assessment for patients with pulmonary arterial hypertension, researchers reported in Chest.

“REVEAL Lite 2 was developed to provide clinicians with a simplified risk calculation method that can be routinely implemented in clinical practice, where data for patients may lack and be time-constrained,” Raymond L…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.